Valve risk leads to withdrawal of pergolide (Permax, Valiant)

Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.